Department of Biomedical and Biotechnological Sciences, University of Catania, 95123, Catania, Italy.
Department of Medical and Surgical Sciences and Advanced Technologies, F. Ingrassia, University of Catania, 95123, Catania, Italy.
J Transl Med. 2023 Nov 3;21(1):780. doi: 10.1186/s12967-023-04664-9.
Follicular thyroid cancer (FTC) is a prevalent form of differentiated thyroid cancer, whereas anaplastic thyroid cancer (ATC) represents a rare, fast-growing, undifferentiated, and highly aggressive tumor, posing significant challenges for eradication. Ferroptosis, an iron-dependent cell death mechanism driven by the excessive production of reactive oxygen species and subsequent lipid peroxidation, emerges as a promising therapeutic strategy for cancer. It has been observed that many cancer cells exhibit sensitivity to ferroptosis, while some other histotypes appear to be resistant, by counteracting the metabolic changes and oxidative stress induced by iron overload.
Here we used human biopsies and in vitro approaches to analyse the effects of iron-dependent cell death. We assessed cell proliferation and viability through MTT turnover, clonogenic assays, and cytofluorimetric-assisted analysis. Lipid peroxidation assay and western blot were used to analyse molecular mechanisms underlying ferroptosis modulation. Two distinct thyroid cancer cell lines, FTC-133 (follicular) and 8505C (anaplastic), were utilized. These cell lines were exposed to ferroptosis inducers, Erastin and RSL3, while simulating an iron overload condition using ferric ammonium citrate.
Our evidence suggests that FTC-133 cell line, exposed to iron overload, reduced their viability and showed increased ferroptosis. In contrast, the 8505C cell line seems to better tolerate ferroptosis, responding by modulating CD71, which is involved in iron internalization and seems to have a role in resistance to iron overload and consequently in maintaining cell viability.
The differential tolerance to ferroptosis observed in our study may hold clinical implications, particularly in addressing the unmet therapeutic needs associated with ATC treatment, where resistance to ferroptosis appears more pronounced compared to FTC.
滤泡状甲状腺癌(FTC)是一种常见的分化型甲状腺癌,而间变性甲状腺癌(ATC)则是一种罕见的、快速生长的、未分化的、高度侵袭性的肿瘤,对其根除构成了重大挑战。铁死亡是一种由活性氧(ROS)过度产生和随后的脂质过氧化驱动的铁依赖性细胞死亡机制,它为癌症的治疗提供了一种很有前途的策略。已经观察到,许多癌细胞对铁死亡敏感,而其他一些组织型似乎对铁死亡有抗性,它们通过抵消铁过载引起的代谢变化和氧化应激来实现。
我们使用人类活检标本和体外方法来分析铁依赖性细胞死亡的影响。我们通过 MTT 转换、集落形成测定和细胞荧光辅助分析来评估细胞增殖和活力。我们使用脂质过氧化测定和蛋白质印迹来分析铁死亡调节的分子机制。我们使用了两种不同的甲状腺癌细胞系,FTC-133(滤泡状)和 8505C(间变性),它们被暴露于铁死亡诱导剂 Erastin 和 RSL3 中,同时使用柠檬酸铁铵模拟铁过载条件。
我们的证据表明,暴露于铁过载的 FTC-133 细胞系降低了它们的活力,并表现出增加的铁死亡。相比之下,8505C 细胞系似乎更好地耐受铁死亡,通过调节 CD71 来做出反应,CD71 参与铁内化,并且似乎在抵抗铁过载和维持细胞活力方面发挥作用。
我们的研究观察到的对铁死亡的不同耐受可能具有临床意义,特别是在解决与 ATC 治疗相关的未满足的治疗需求方面,与 FTC 相比,ATC 对铁死亡的抵抗似乎更为明显。